Imvotamab bridges CD3+ T cells to CD20+ cells to trigger T‑cell–mediated killing (perforin/granzyme apoptosis) and, via its IgM format, activates complement to induce complement-dependent cytotoxicity (CDC) of CD20-expressing cells.